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ABBREVIATIONS 
AD: Alzheimer’s disease 
bvFTD: Behavioural variant frontotemporal dementia 
CSF: Cerebrospinal Fluid 
FAB: Frontal Assessment Battery 
MMSE: Mini Mental State Examination 
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Background: Emotion deficits are a recognised biomarker for behavioural variant frontotemporal 
dementia (bvFTD), but recent studies have reported emotion deficits also in Alzheimer’s disease 
(AD).  
Methods: A hundred and twenty-three participants (33 AD, 60 bvFTD, 30 controls) were 
administered a facial emotion recognition test, to investigate the clinical factors influencing the 
diagnostic distinction on this measure. Binomial regression analysis revealed that facial emotion 
recognition in AD was influenced by disease duration and MMSE, whereas the same was not true 
for bvFTD. Based on this information, we median-split the AD group on disease duration (3 
years) or MMSE (24) and compared the facial emotion recognition performance of mild-AD, 
moderate-AD, bvFTD patients and controls. 
Results: Results showed that very mild-AD performed consistently at control levels for all 
emotions. By contrast, mild/moderate-AD and bvFTD were impaired compared to controls on 
most emotions. Interestingly, mild/moderate-AD were significantly impaired compared to very 
mild-AD on total score, anger and sadness subscores. Logistic regression analyses corroborated 
these findings with ~94% of very mild-AD being successfully distinguished from bvFTD at 
presentation, while this distinction was reduced to ~78% for mild/moderate-AD.  
Conclusions: Facial emotion recognition in AD is influenced by disease progression, with very 
mild-AD being virtually intact for emotion performance. Mild/moderate-AD and bvFTD show 
consistent impairment in emotion recognition, with bvFTD being worse. A disease progression of 
over 3 years or a MMSE lower than 24 should warrant caution to put too much emphasis on 
emotion recognition performance in the diagnostic distinction of AD and bvFTD.  
 
Key words: frontotemporal dementia, bvFTD, emotion, Alzheimer’s disease 
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INTRODUCTION 
Emotion recognition deficit is a hallmark feature of behavioural variant frontotemporal dementia 
(bvFTD) [1] and has therefore substantial diagnostic potential to distinguish bvFTD from other 
neurodegenerative diseases, such as Alzheimer’s disease (AD) [2]. Nevertheless, AD patients have 
also been reported to show emotion recognition deficits in some studies [3] but not others [4]. The 
current study explores the clinical factors that influence facial emotion recognition in AD, which 
will inform future diagnoses of both diseases. For this purpose, we compare the facial emotion 
recognition performance in a large sample of AD and bvFTD patients and controls. A subset of 
patients had patho-physiological confirmation via cerebrospinal fluid (CSF) biomarkers 
 
METHODS 
Participants.  
 Thirty-three AD and 60 bvFTD patients, as well as 30 age- and education-matched controls 
were recruited via the Memory and Alzheimer Institute of the Pitié-Salpêtrière Hospital in Paris 
(France). BvFTD and AD patients fulfilled the disease specific diagnostic criteria [5,6]. Controls 
were included according to the following criteria: Mini mental state examination (MMSE) score ≥ 
27/30; no history of neurological or psychiatric disorders; no memory complaint or cognitive 
impairment. 
  CSF biomarkers (Aß42, Tau and P-Tau) were available for 32 patients (n=12 AD, n=24 
bvFTD). All AD patients had an “AD CSF biomarker profile” as previously defined [7], whereas 
bvFTD patients did not. CSF data was not available for control subjects. Two bvFTD patients had 
known genetic mutations (1 MAPT, 1 PGRN).  
 According to French legislation, explicit informed consent for patients was waived. For the 
healthy control subjects, the study was approved by the local Ethics Committee.  
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Facial emotion recognition test. 
Thirty-five Ekman faces were presented in a validated computerized test [8] and 
patients indicated which emotion was expressed (emotion labels were provided during the 
entire task). Seven different emotions were presented 5 times in a pseudorandom order 
(Happiness, Fear, Disgust, Neutral, Surprise, Anger and Sadness). Percentage of correct 
responses for each emotion and for the total emotion performance was calculated. 
 
Statistics.  
Data were analyzed using SPSS20 (IBM, Armonk, NY). Prior to any analysis, variables 
were plotted and checked for normality of distribution via Shapiro-Wilk tests. Demographic and 
neuropsychological data were analyzed across the groups via ANOVAs and Mann-Whitney tests, 
except for age, a normally distributed variable, which was analysed with Student t test. 
Correlations were performed through Spearman’s rank correlation coefficient. 
For facial emotion recognition test, Shapiro-Wilk tests were not significant for bvFTD and 
control groups, indicating normal distributions. By contrast, emotion recognition performance 
in AD was non-normally distributed (Shapiro-Wilk: p < .05), which was further corroborated 
by a high frequency mode score (85.71) and a low Kurtosis coefficient (-0.93) in the AD 
group. These results suggest that the AD group is not homogeneous in its emotion 
performance and that facial emotion recognition is potentially influenced by other variables. 
To elucidate this further, we ran a correlation analysis on the demographic, clinical and 
biological variables (age, education level, disease duration, MMSE and CSF biomarkers: 
Aß42, Tau and P-Tau) to estimate their influence on the emotion performance in AD. Results 
showed that MMSE (R=0.47; p < .005) and disease duration (R=-0.51; p < .005) were 
significantly correlated with total facial emotion recognition in AD. Interestingly, CSF-Tau 
level, reflecting neuronal and axonal degeneration and formation of neurofibrillary tangles 
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[9,10], was also significantly correlated (R=-0.63; p < .05) with facial emotion recognition in 
the subgroup of AD with available tau data. No variables correlated with the emotion 
recognition in bvFTD. Based on the convergent links between emotion recognition and 
progression in AD, we decided therefore to conduct 2 analyses. In the first one, the overall 
AD group was contrasted with bvFTD and controls. In the second analysis, we contrasted 
very mild-AD and mild/moderated-AD with bvFTD and controls, by median-splitting the AD 
group via two proxy measures for disease severity: i) via disease duration (median=3 years) 
into a very mild (n=14, mean=1.7 year) and a mild/moderate (n=16, mean=5.3 year) group (3 
patients were excluded from this analysis because disease duration was not available) and, ii) 
in a separate analysis, via low (n=15, MMSE mean=21.7) and high (n=18, MMSE 
mean=25.7) MMSE (median=24). Due to converging results between disease duration and 
MMSE analyses, only the results from the first analysis (disease duration median-split) are 
presented here in detail. 
We also performed logistic regressions using Enter method in order to test changes in 
diagnostic accuracy (AD vs bvFTD) for facial emotion recognition as a function of disease 
progression. 
 
RESULTS 
Demographics, neuropsychological and facial emotion recognition scores for all three 
groups are presented in Table 1. Comparisons of bvFTD, AD and control groups revealed no 
significant difference for gender, education and disease duration. However, patients with AD were 
significantly older (t=2.7; p < .05) than bvFTD patients. Importantly, very mild-AD and 
mild/moderate-AD did not differ significantly on age, gender, education and the Frontal 
Assessment Battery (FAB) but MMSE was significantly higher in very mild-AD (Z=-2.4; p < .05). 
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Facial emotion recognition – AD vs. bvFTD 
For this analysis, age was added as a covariate. On the total score, controls performed 
significantly better than AD and bvFTD (Z=-6.9; p < .0001), with bvFTD significantly impaired 
(Z=-4.8; p < .0001) in comparison to AD (Figure 1A). Across emotion subscores, bvFTD 
performed significantly worse than controls (all p < .0001) and AD (all p<.01), except for 
Happiness and Neutral, which were not significantly different between AD and bvFTD. AD 
patients were only impaired on the happiness (Z=-1.9; p < .05) and sadness subscores compared to 
controls (Z=-2.4; p < .01), with a non-significant trend for neutral (p=.07).  
Comparisons between bvFTD patients with and without patho-physiological CSF 
confirmation showed no differences on any measure. Similarly, no significant differences were 
also observed for AD subgroups.  
 
Facial emotion recognition – very mild AD vs. mild/moderate AD vs. bvFTD 
Median-splitting of the AD group based on disease duration demonstrated no significant 
difference on total emotion recognition score between the very mild-AD group and controls, but 
the very mild-AD group performed significantly better (Z=-4.9; p < .0001) than bvFTD (Figure 
1B). By contrast, mild/moderate-AD patients were significantly impaired compared to controls 
(Z=-4.3; p < .0001) and very mild-AD (Z=-3.7; p < .0001) and performed better than bvFTD (Z=-
2.5; p < .05). These results were identical when median-splitting the AD group based on the 
MMSE score. 
Analyses of the emotion subscores revealed a similar picture, with no significant difference 
between very mild-AD and controls. By contrast, mild/moderate-AD performed worse than 
controls for happiness (p < .01), disgust (p < .05), neutral (p < .01), surprise (p < .05), anger (p < 
.05) and sadness (p < .0001). Mild/moderate-AD also performed significantly worse than very 
mild-AD for sadness (Z=-3.3; p = .001) and anger (Z=-2.4; p < .05), with a trend towards 
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significance for disgust (p=.09).  
Comparisons with bvFTD for emotion subscores showed that very mild-AD patients 
performed significantly better than bvFTD on all emotions (p<.005) except happiness (p>.1). 
Compared to mild/moderate-AD, bvFTD patients performed worse for anger (Z=-2.7; p < .01) and 
sadness (Z=-2.3; p < .05). A similar pattern was observed when median-splitting the AD group on 
the MMSE score. 
 
Logistic regression analyses. 
 Logistic regression (ENTER method) revealed facial emotion recognition distinguished 
between bvFTD and AD in 76.7% of cases. This distinction increased when contrasting bvFTD 
and very mild-AD (94.6%) but was similar between bvFTD and mild/moderate-AD (78.9%). 
 
 
DISCUSSION 
Our results indicate that facial emotion recognition performance in AD is influenced by the 
disease duration and overall cognitive impairment as measured by the MMSE, which are both 
proxies of disease progression/severity. Furthermore, while this result should be further replicated 
in a greater sized group, facial emotion recognition in AD seems also linked to the level of Tau 
protein deposition, a CSF marker of neuronal and axonal degeneration and formation of 
neurofibrillary tangles [9,10]. Although these findings are cross-sectional and not longitudinal, they 
indicate a clear decline in the recognition of emotion with the progression of AD by the 
convergence of clinical, cognitive and biological data. The observed differences between very 
mild and mild/moderate AD patients might also explain previous inconsistent AD findings [2-4], 
due to different admixtures of patients at different disease stages.  In addition, our results inform 
the diagnostic distinction of bvFTD and AD. Emotion deficits have been regarded as a hallmark 
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for bvFTD but not AD and thus are now included as diagnostic markers for possible bvFTD [5]. 
Our results confirm that bvFTD are consistently impaired on emotion recognition and can be 
distinguished from very mild-AD in over 94% of presenting cases. However, distinction from 
mild/moderate-AD resulted in lower accuracy (~78%). Taken together, these results suggest 
disease progression (disease duration or MMSE) should be taken into account during the 
diagnostic evaluation of facial emotion recognition in AD and bvFTD. In particular a disease 
duration longer than 3 years or an MMSE score lower than 24, which were the median-split cut-
offs in our study, should warrant caution to put too much emphasis on facial emotion recognition 
performance in the diagnostic distinction between AD and bvFTD.  
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Legend of Figure 1 
 
Title: Percentage of correct answers in the facial emotion recognition test for controls, 
AD and bvFTD patients (A). Percentage of correct answers in the facial emotion 
recognition test after disease duration split in the AD group (B).  
 
Legend: 
* Indicates a significant difference. Abbreviations: AD: Alzheimer’s disease; bvFTD: 
behavioral version of frontotemporal dementia. 
 
